1-5 of 5
Authors: Toshio Imai
Journal Article
Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate Get access
Modern Rheumatology, Volume 34, Issue 1, January 2024, Pages 37–44, https://doi.org/10.1093/mr/road004
Published: 21 January 2023
Journal Article
Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs Get access
Modern Rheumatology, Volume 34, Issue 1, January 2024, Pages 45–49, https://doi.org/10.1093/mr/road005
Published: 21 January 2023
Journal Article
A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs Get access
Modern Rheumatology, Volume 31, Issue 4, 4 July 2021, Pages 783–789, https://doi.org/10.1080/14397595.2020.1868675
Published: 04 July 2021
Journal Article
Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis Get access
Modern Rheumatology, Volume 28, Issue 1, 2 January 2018, Pages 58–65, https://doi.org/10.1080/14397595.2017.1337056
Published: 02 January 2018
Journal Article
Fractalkine/CX3CL1 in rheumatoid arthritis Get access
Modern Rheumatology, Volume 27, Issue 3, 4 May 2017, Pages 392–397, https://doi.org/10.1080/14397595.2016.1213481
Published: 04 May 2017
